RSC Advances Blog

Cancer is a devastating disease which kills millions of people each year. Although treatment for cancer has come a long way, current treatment relies on using toxic chemotherapeutic drugs, which can also kill healthy cells causing terrible side effects for patients. Nanotechnology and nanvectors have emerged as a new strategy in cancer treatment, as they protect the drugs from premature degradation, and improve the pharmacodynamics of the drugs. However, very few nanovector-based drugs are currently available.

In this work, Sudipta Basu and co-workers, from Pune, India, have developed a novel nanovector from lithocholic acid (LA), a naturally occuring bile acid. The nanoparticles can self-assemble to develop supramolecular nanostructures, and are under 200 nm in size which is beneficial for targeting tumours by enhanced permeability and retention. The nanoparticles can hold the clinically approved cytotoxic drugs doxorubicin, paclitaxel and PI103, and release the active drugs in a controlled manner at pH 5.5. They can also be decorated with antibodies, aptamers or cell surface receptor targeting peptides, for tissue specific delivery of cytotoxic drugs.

Read the full article to find out more. It’s free to access for 4 weeks!

Novel self-assembled lithocholic acid nanoparticles for drug delivery in cancer, Sumersing Patil, Sohan Patil, Suhas Gawali, Shrikant Shende, Shraddha Jadhav and Sudipta Basu, RSC Advances, 2013, DOI: 10.1039/c3ra42994f

Sara Coles is a guest web-writer for RSC Advances. She currently works for Johnson Matthey in Royston, UK.

Jiahong Li and colleagues at Chengdu Institute of Organic Chemistry in China have prepared water-soluble ligands to allow transition metal catalysed asymmetric transfer hydrogenation (ATH) of aromatic ketones, especially aromatic ketones with a bromine group in the alpha position. They produced the expected alcholos with ees up to 96% and the catalyst could be reused at least 21 times.

The reactions were carried out in the presence of cationic surfactant CTAB (cetyltrimethylammonium bromide). Of the three catalytic metals tested, ruthenium, iridium and rhodium, they report that the best results were obtained using ruthenium.

Products synthesised using the novel catalyst system included key pharmaceutical intermediates for anti-asthma drugs, terbutaline and salbutamol.

Read more about the experimental work in RSC Advances:

Surfactant-accelerated asymmetric transfer hydrogenation with recyclable water-soluble catalyst in aqueous media, Jiahong Li, Xuefeng Li, Yaping Ma, Jiashou Wu, Fei Wang, Jing Xiang, Jin Zhu, Qiwei Wang and Jingen Deng, RSC Adv., 2013, 3, 1825

This article is free to access for 4 weeks!